Shares of STAAR Surgical (NASDAQ:STAA) have received an average recommendation of “Buy” from the six ratings firms that are currently covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $42.00.

Several research firms recently issued reports on STAA. ValuEngine lowered shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Zacks Investment Research lowered shares of Farmland Partners from a “hold” rating to a “sell” rating in a research note on Friday, July 12th. BidaskClub raised shares of Xilinx from a “hold” rating to a “buy” rating in a research note on Wednesday, July 24th. Finally, Canaccord Genuity reduced their price objective on shares of Jamieson Wellness from C$23.00 to C$20.00 in a research note on Monday, May 6th.

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. acquired 100,000 shares of STAAR Surgical stock in a transaction that occurred on Friday, May 3rd. The stock was acquired at an average price of $22.23 per share, with a total value of $2,223,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 4.30% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in STAA. KAMES CAPITAL plc bought a new position in STAAR Surgical in the 2nd quarter worth $3,366,000. Gilder Gagnon Howe & Co. LLC increased its holdings in shares of STAAR Surgical by 418.9% during the 1st quarter. Gilder Gagnon Howe & Co. LLC now owns 119,869 shares of the medical instruments supplier’s stock worth $4,098,000 after purchasing an additional 96,768 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of STAAR Surgical by 162.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 151,780 shares of the medical instruments supplier’s stock worth $4,843,000 after purchasing an additional 93,940 shares during the period. Roubaix Capital LLC bought a new position in shares of STAAR Surgical during the 2nd quarter worth about $2,556,000. Finally, Cortina Asset Management LLC increased its holdings in shares of STAAR Surgical by 47.3% during the 2nd quarter. Cortina Asset Management LLC now owns 268,448 shares of the medical instruments supplier’s stock worth $7,887,000 after purchasing an additional 86,184 shares during the period. Hedge funds and other institutional investors own 89.71% of the company’s stock.

Shares of NASDAQ:STAA traded down $0.56 during trading on Thursday, reaching $30.30. 650,700 shares of the company traded hands, compared to its average volume of 430,513. The company has a fifty day simple moving average of $29.62. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of 108.21 and a beta of 2.32. STAAR Surgical has a 1-year low of $21.70 and a 1-year high of $54.00. The company has a current ratio of 5.41, a quick ratio of 4.83 and a debt-to-equity ratio of 0.04.

STAAR Surgical (NASDAQ:STAA) last released its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.06. STAAR Surgical had a net margin of 4.44% and a return on equity of 13.22%. The business had revenue of $32.58 million during the quarter, compared to analyst estimates of $32.40 million. During the same quarter in the previous year, the business earned $0.01 EPS. As a group, research analysts anticipate that STAAR Surgical will post 0.33 EPS for the current fiscal year.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

Further Reading: What are the disadvantages of after-hours trading?

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.